Concepedia

Author

Sabine Pinnetti

Boehringer Ingelheim (Germany)

Also Known As

S Pinnetti, S. Pinnetti, Sabine Pinnetti

27

Publications

1.8K

Citations

17

H-Index

15

Concepts

All Affiliations

Boehringer Ingelheim (Germany)Boehringer Ingelheim (United States)Dallas Diabetes Research CenterProfil Institute for Metabolic ResearchBoehringer Ingelheim (France)
SP

About

Sabine Pinnetti is an author at Boehringer Ingelheim (Germany) specializing in pharmacotherapy, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

357

2

Pharmacology

8

8

357

3

Diabetes

5

5

260

4

Clinical Pharmacology

2

2

49

5

Drug Monitoring

1

1

18

Sabine Pinnetti

×

20

Publications

1.8K

Citations

17

H-Index

YearCitations

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Tim Heise, Elke Seewaldt-Becker, Sreeraj Macha,

Diabetes Obesity and Metabolism

2013

261

Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin

Ele Ferrannini, Andreas Berk, Stefan Hantel,

Diabetes Care

2013

218

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Julio Rosenstock, Leo Seman, Ante Jelaska,

Diabetes Obesity and Metabolism

2013

208

A <scp>P</scp> hase <scp>IIb</scp> , randomized, placebo‐controlled study of the <scp>SGLT2</scp> inhibitor empagliflozin in patients with type 2 diabetes

Ele Ferrannini, Leo Seman, Elke Seewaldt-Becker,

Diabetes Obesity and Metabolism

2013

177

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

Leo Seman, Sreeraj Macha, Gerhard Nehmiz,

Clinical Pharmacology in Drug Development

2013

134

Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes

Hannele Yki‐Järvinen, Julio Rosenstock, S. Durán‐García,

Diabetes Care

2013

132

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus

Tim Heise, Leo Seman, Sreeraj Macha,

Diabetes Therapy

2013

118

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( <scp>SGLT2</scp> ) inhibitor, in subjects with renal impairment

Sreeraj Macha, Michaela Mattheus, Atef Halabi,

Diabetes Obesity and Metabolism

2013

108

Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy

Jan Galle, Edzard Schwedhelm, Sabine Pinnetti,

Nephrology Dialysis Transplantation

2008

95

Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment

Sreeraj Macha, Peter W. Rose, Michaela Mattheus,

Diabetes Obesity and Metabolism

2013

65

Page 1